AAI/CML claims clinical material production time reductions of 65%

By .

- Last updated on GMT

Image: iStock/Supertruper
Image: iStock/Supertruper

Related tags: Pharmacology

AAIPharma and Cambridge Major Labs (CML) under a merged entity have driven efficiencies in end-to-end drug manufacturing, the firm says, dramatically reducing material delivery time.

AAI Pharma and CML merged in 2013​, to form a full-service contract manufacturing organisation (CMO) and two-and-a-half years on the firm has said the integration between the two units has led to “dramatic advancements in efficiency.”

According to the CMO, it has managed to manufacture and release late-stage clinical trial materials from an active pharmaceutical ingredient (API) made under GMP, through to the sterile drug product within 79 days.

This is around 65% of the 230 days AAI/CML said is the industry standard for non-integrated approaches, and marks the first time the company has produced both GMP API and GMP Drug Product in continuous end-to-end fashion.

“We have streamlined and integrated to create world class solution for small to mid-sized pharma & biotech companies for clinical trial material by providing a broad range of services across all seven of our sites and businesses,”​ CEO Stephan Kutzer said in a statement.

“Our technical and regulatory expertise differentiates AAI/CML as we proactively guide and advise our clients through all the clinical phases. The integrated manufacturing services further complement our ProForm SelectTM service offering for a fuller end-to-end solution.”

The announcement comes weeks after the CMO announced it was investing $11m (€10m)​ into a new facility at its Cortex innovation centre in St Louis, Missouri.

Related news

Show more

Related products

show more

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars